Unknown

Dataset Information

0

Anti-PD-L1 (atezolizumab) as an immune primer and concurrently with extended-field chemoradiotherapy for node-positive locally advanced cervical cancer.


ABSTRACT: BACKGROUND:There is a lack of data exploring the use and optimal timing of immunotherapy and chemoradiation therapy (CRT) in node-positive cervical cancer. Further translational research into mechanisms of response and resistance to immunotherapy in advanced cervical cancer is warranted. PRIMARY OBJECTIVES:To determine if sequencing of atezolizumab and CRT result in differential immune activation, as determined by clonal expansion of T cell receptor beta (TCRB) repertoires in peripheral blood on day 21. STUDY HYPOTHESIS:There is a difference for clonal expansion of T cell receptor beta repertoires in the peripheral blood at day 21 between the priming and concurrent atezolizumab and CRT in Arm A vs the concurrent atezolizumab and CRT in Arm B. TRIAL DESIGN:Locally advanced cervical cancer patients with lymph node-positive disease will be randomized on this open-label, randomized trial with two experimental arms. Arm A will get one dose of atezolizumab prior to cisplatin CRT, and then two subsequent doses of atezolizumab during the CRT, and Arm B will get three doses during CRT. Patients will be followed for 2 years to assess outcomes. MAJOR INCLUSION/EXCLUSION CRITERIA:Patients must have histologically confirmed, newly diagnosed advanced cervical cancer (squamous cell carcinoma, adenocarcinoma, and adenosquamous cell carcinoma): FIGO 2009 clinical stages IB2/IIA with positive para-aortic nodes, or FIGO 2009 clinical stages IIB/IIIB/IVA with positive pelvic or para-aortic lymph nodes. Exclusion criteria include those who had a prior hysterectomy or lymph node dissection. PRIMARY ENDPOINTS:Clonal expansion of TCRB) repertoires in peripheral blood on day 21. SAMPLE SIZE:The sample size will be 40 patients. ESTIMATED DATES FOR COMPLETING ACCRUAL AND PRESENTING RESULTS:We estimate accrual to finish by the summer of 2020 with presentation of results to follow in 2021. TRIAL REGISTRATION:NCT03738228.

SUBMITTER: Mayadev J 

PROVIDER: S-EPMC7310564 | biostudies-literature | 2020 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Anti-PD-L1 (atezolizumab) as an immune primer and concurrently with extended-field chemoradiotherapy for node-positive locally advanced cervical cancer.

Mayadev Jyoti J   Zamarin Dmitriy D   Deng Wei W   Lankes Heather H   O'Cearbhaill Roisin R   Aghajanian Carol A CA   Schilder Russell R  

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20191222 5


<h4>Background</h4>There is a lack of data exploring the use and optimal timing of immunotherapy and chemoradiation therapy (CRT) in node-positive cervical cancer. Further translational research into mechanisms of response and resistance to immunotherapy in advanced cervical cancer is warranted.<h4>Primary objectives</h4>To determine if sequencing of atezolizumab and CRT result in differential immune activation, as determined by clonal expansion of T cell receptor beta (TCRB) repertoires in peri  ...[more]

Similar Datasets

| S-EPMC9128530 | biostudies-literature
| S-EPMC7271386 | biostudies-literature
| S-EPMC5514103 | biostudies-literature
| S-EPMC8468141 | biostudies-literature
| S-EPMC5685743 | biostudies-literature
| S-EPMC6367228 | biostudies-literature
2021-02-04 | GSE165252 | GEO
| S-EPMC5289227 | biostudies-literature
| S-EPMC6369970 | biostudies-literature
| S-EPMC5516873 | biostudies-literature